By Colin Kellaher
Foghorn Therapeutics on Monday said it is ending independent development of its FHD-286 drug candidate following disappointing results from an early-stage study.
Foghorn said the objective clinical response rate observed in the Phase 1 dose-escalation study of FHD-286 in combination with decitabine in acute myeloid leukemia didn't meet the threshold for the Cambridge, Mass., clinical-stage biotechnology company to continue development of the drug on its own.
Foghorn said it is evaluating partnerships and investigator-sponsored trials to advance FHD-286, adding that it will now prioritize its other pipeline candidates and its collaboration programs with Eli Lilly.
The company said its $267.4 million in cash, equivalents and marketable securities as of Sept. 30 provide a runway into 2027.
Trading in shares of Foghorn, which closed Friday at $5.30, was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 16, 2024 07:35 ET (12:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.